Hlib Chabaniuk

Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response

Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response
Greenwich FLAMINGO-01 sparks patent push

Greenwich LifeSciences, Inc. has announced the pursuit of new patent claims stemming from the statistically significant open label immune response and recurrence rate data generated in its FLAMINGO-01 study.

The company suggests these updated claims could enhance the intellectual property protection associated with its lead immunotherapy candidate as clinical results demonstrate further potential. No additional details on the patent filing timeline or scope were disclosed.

Greenwich LifeSciences previously outlined its upcoming plans for the AACR Meeting, indicating ongoing company developments related to its pipeline projects. Details of the update were disclosed in the company’s announcement regarding its AACR Meeting plans. The company continues to report progress tied to its immunotherapy candidate.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.